Cargando…
Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819520/ https://www.ncbi.nlm.nih.gov/pubmed/31661009 http://dx.doi.org/10.1186/s40360-019-0362-2 |
_version_ | 1783463750372687872 |
---|---|
author | Liu, Guohui Wang, Chunbo He, Yunlong E, Mingyan |
author_facet | Liu, Guohui Wang, Chunbo He, Yunlong E, Mingyan |
author_sort | Liu, Guohui |
collection | PubMed |
description | BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumours. The aim of this study was to investigate the efficacy of apatinib in patients with advanced malignant tumours and failure of standard therapy. METHODS: We collected 41 patients with advanced malignant tumours in our department; all tumours were pathologically confirmed as malignant. All patients received apatinib after failure of standard therapy: 500 mg/dose, one dose/d, orally 30 min after a meal, until progressive disease or intolerable adverse reactions occurred. When there was a second- or third-degree adverse reaction associated with apatinib during treatment, apatinib treatment could be suspended or reduced to 250 mg/dose. Clinical efficacy and progression-free survival were assessed according to RECIST1.1, and adverse reactions were observed. RESULTS: Efficacy assessment was available for 31 patients with a median progression-free survival time of 2.66 months; the objective response rate and disease control rates were 16.1 and 64.5%, respectively. The disease control rates of the patients with lower Eastern Cooperative Oncology Group scores (1–2 points) and with fewer metastatic sites (< 3 sites) were higher than those of the patients with higher scores (3 points) and with more metastatic sites (≥3 sites), respectively (all P < 0.05). The most common adverse reactions were hypertension, neutropenia and hand-foot syndrome. CONCLUSION: For patients with advanced malignant tumours with failure of standard therapy, administration of apatinib can still result in good efficacy. The efficacy of apatinib is better in patients with a higher performance status and lower degree of tumour progression. |
format | Online Article Text |
id | pubmed-6819520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68195202019-10-31 Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours Liu, Guohui Wang, Chunbo He, Yunlong E, Mingyan BMC Pharmacol Toxicol Research Article BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumours. The aim of this study was to investigate the efficacy of apatinib in patients with advanced malignant tumours and failure of standard therapy. METHODS: We collected 41 patients with advanced malignant tumours in our department; all tumours were pathologically confirmed as malignant. All patients received apatinib after failure of standard therapy: 500 mg/dose, one dose/d, orally 30 min after a meal, until progressive disease or intolerable adverse reactions occurred. When there was a second- or third-degree adverse reaction associated with apatinib during treatment, apatinib treatment could be suspended or reduced to 250 mg/dose. Clinical efficacy and progression-free survival were assessed according to RECIST1.1, and adverse reactions were observed. RESULTS: Efficacy assessment was available for 31 patients with a median progression-free survival time of 2.66 months; the objective response rate and disease control rates were 16.1 and 64.5%, respectively. The disease control rates of the patients with lower Eastern Cooperative Oncology Group scores (1–2 points) and with fewer metastatic sites (< 3 sites) were higher than those of the patients with higher scores (3 points) and with more metastatic sites (≥3 sites), respectively (all P < 0.05). The most common adverse reactions were hypertension, neutropenia and hand-foot syndrome. CONCLUSION: For patients with advanced malignant tumours with failure of standard therapy, administration of apatinib can still result in good efficacy. The efficacy of apatinib is better in patients with a higher performance status and lower degree of tumour progression. BioMed Central 2019-10-28 /pmc/articles/PMC6819520/ /pubmed/31661009 http://dx.doi.org/10.1186/s40360-019-0362-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Liu, Guohui Wang, Chunbo He, Yunlong E, Mingyan Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title | Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title_full | Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title_fullStr | Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title_full_unstemmed | Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title_short | Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
title_sort | application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819520/ https://www.ncbi.nlm.nih.gov/pubmed/31661009 http://dx.doi.org/10.1186/s40360-019-0362-2 |
work_keys_str_mv | AT liuguohui applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours AT wangchunbo applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours AT heyunlong applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours AT emingyan applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours |